# Intellia Therapeutics

Intellia Therapeutics is an other based in Cambridge, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Assets under management:** Undisclosed
- **Website:** intelliatx.com
- **LinkedIn:** https://www.linkedin.com/company/intelliatx

## Regulatory record

- **Reports private funds:** No

## About

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.

## Sectors

- Biotech
- Genome Editing
- Therapeutics

## People

- John Leonard — President and Chief Executive Officer
- James Basta — Executive Vice President, General Counsel and Corporate Secretary
- Eliana Clark — Chief Technical Officer
- Edward Dulac — Chief Financial Officer
- David Lebwohl — Chief Medical Officer
- Birgit Schultes — Chief Scientific Officer

## Questions

### Who runs investment decisions at Intellia Therapeutics?

Intellia Therapeutics is a publicly traded biotechnology company, so investment decisions are made by its board of directors and executive team, led by CEO John Leonard, M.D. (appointed January 2018). Key executives include CFO Edward Dulac and Chief Medical Officer David Lebwohl, M.D. The board is chaired by Frank Verwiel, M.D., and includes experienced pharma and biotech investors.

### How does Intellia source proprietary technology and deal flow?

Intellia develops its CRISPR-based therapies in-house, leveraging its core gene-editing platform and partnerships. The company collaborates with Regeneron on liver-directed programs, co-founded AvenCell for allogeneic CAR-T therapies with Blackstone Life Sciences, and has a licensing agreement with Kyverna Therapeutics for autoimmune cell therapies. It also scouts cutting-edge technologies to advance its platform.

### What are Intellia's lead therapeutic programs and pipeline status?

Intellia's most advanced programs target hereditary angioedema (HAE) and ATTR amyloidosis, both in late-stage clinical development. The company uses in vivo CRISPR editing to treat these genetic diseases. Additional pipeline candidates include ex vivo engineered cell therapies for cancer and autoimmune indications, with partnerships for allogeneic CAR-T programs via AvenCell and Kyverna.

### How is Intellia related to Jennifer Doudna and her Nobel Prize work?

Jennifer Doudna, who shared the 2020 Nobel Prize in Chemistry for co-developing CRISPR-Cas9 gene editing, is a co-founder of Intellia Therapeutics. The company was built to translate that foundational science into human therapeutics. Doudna does not serve in a management role at Intellia, but the firm's platform directly descends from the CRISPR technology she pioneered.

### Does Intellia have any partnerships or collaborations with large pharma?

Yes. Intellia has a major collaboration with Regeneron to research, develop, and commercialize CRISPR-based therapies for liver diseases, including its lead ATTR amyloidosis program. Additionally, it co-founded AvenCell with Blackstone Life Sciences for allogeneic CAR-T cell therapy. The firm also partners with Kyverna Therapeutics on autoimmune disease cell therapies.

### What is Intellia's approach to manufacturing and commercialization?

Intellia is building a fully integrated commercial infrastructure under the leadership of Chief Technical Officer Eliana Clark, who oversees manufacturing, supply chain, process development, and quality. The firm intends to become a self-sustaining biopharmaceutical company with capabilities from drug discovery through commercialization, rather than licensing out its products.

## Related profiles

- [CJ Group](https://altss.com/profile/cj-group)
- [Jio Platforms Limited](https://altss.com/profile/jio-platforms-limited)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/intellia-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology